Dechra Pharmaceuticals PLC Director/PDMR Shareholding (2548O)
06 Ottobre 2021 - 04:40PM
UK Regulatory
TIDMDPH
RNS Number : 2548O
Dechra Pharmaceuticals PLC
06 October 2021
6 October 2021
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
Dechra Pharmaceuticals PLC announces that on 5 October 2021,
Paul Sandland, Executive Director and PDMR exercised market value
options over ordinary shares of 1p each in the Company. The options
were granted under the Dechra Pharmaceuticals 2017 Long Term
Incentive Plan as detailed below before Paul Sandland's appointment
as an Executive Director. The exercise of the options was subject
to the achievement of performance conditions which were satisfied
to the extent that the options vested at 100%. Paul Sandland sold
3,960 of the shares acquired to fund the exercise prices and tax
liabilities arising in connection with the exercises of the
unapproved share options, and retained the remaining 2,040
shares.
Date of Scheme Number of Option Price Number of shares Sale
Grant options sold Price
exercised
2 March Approved 550 GBP25.06 Nil N/A
2018
2 March
2018 Unapproved 2,450 GBP25.06 1,830 GBP48.285
26 October
2018 Unapproved 3,000 GBP21.66 2,130 GBP48.285
Paul Sandland's total beneficial holding following these
transactions is 9,651 ordinary shares which represents 0.009% of
the total issued share capital.
The Notification of Dealing Forms set out below are provided in
accordance with the requirements of the UK Market Abuse
Regulation.
Notification of Dealing Forms
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Paul Sandland
------------------------------------ -------------------------------------------
2. Reason for the notification
---------------------------------------------------------------------------------
a) Position/status Director/Chief Financial Officer
------------------------------------ -------------------------------------------
b) Initial notification/ Initial Notification
amendment
------------------------------------ -------------------------------------------
3. Details of the Issuer
---------------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
------------------------------------ -------------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
------------------------------------ -------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
---------------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
------------------------------------ -------------------------------------------
b) Nature of the Exercise of options under the Company's
transaction 2017 Long Term Incentive Plan (Approved
Options)
------------------------------------ -------------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBP25.06 550
------------------------------------ --------------------- --------------------
d) Aggregated information
* Aggregate volume
550
GBP25.06
* Price GBP13,783.00
* Total
------------------------------------ -------------------------------------------
e) Date of the transaction 2021.10.05
------------------------------------ -------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------ -------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Paul Sandland
------------------------------------ ---------------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------------
a) Position/status Director/Chief Financial Officer
------------------------------------ ---------------------------------------------
b) Initial notification/ Initial Notification
amendment
------------------------------------ ---------------------------------------------
3. Details of the Issuer
-----------------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
------------------------------------ ---------------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
------------------------------------ ---------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-----------------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
------------------------------------ ---------------------------------------------
b) Nature of the Exercise of options under the Company's
transaction 2017 Long Term Incentive Plan (Unapproved
Options)
------------------------------------ ---------------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBP25.06 2,450
GBP21.66 3,000
------------------------------------ ---------------------- ---------------------
d) Aggregated information
* Aggregate volume
5,450
GBP23.188
* Price
GBP126,377.00
* Total
------------------------------------ ---------------------------------------------
e) Date of the transaction 2021.10.05
------------------------------------ ---------------------------------------------
f) Place of the transaction Outside a trading venue
------------------------------------ ---------------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Paul Sandland
----------------------------------- ----------------------------------------------
2. Reason for the notification
-----------------------------------------------------------------------------------
a) Position/status Director/Chief Financial Officer
----------------------------------- ----------------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------------- ----------------------------------------------
3. Details of the Issuer
-----------------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
----------------------------------- ----------------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
----------------------------------- ----------------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
-----------------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument
ISIN: GB0009633180
Identification
code
----------------------------------- ----------------------------------------------
b) Nature of the Sale of shares obtained under the Company's
transaction 2017 Long Term Incentive Plan (Unapproved
Options)
----------------------------------- ----------------------------------------------
c) Price(s) and volumes(s) Price(s) Volume(s)
GBP 48.285 3,960
----------------------------------- ------------------------- -------------------
d) Aggregated information
* Aggregate volume 3,960
GBP 48.285
* Price GBP191,208.60
* Total
----------------------------------- ----------------------------------------------
e) Date of the transaction 2021.10.05
----------------------------------- ----------------------------------------------
f) Place of the transaction London Stock Exchange
----------------------------------- ----------------------------------------------
For further information, please contact:
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and
related products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products. For more
information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharmaceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBSBDGIXGDGBL
(END) Dow Jones Newswires
October 06, 2021 10:40 ET (14:40 GMT)
Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Mar 2023 a Mar 2024